QIAGEN N.V. (QGEN) Stock Fundamental Analysis
USA - New York Stock Exchange - NYSE:QGEN - NL0015002CX3 - Common Stock
48.1 USD
-0.46 (-0.95%)
48.1 USD
0 (0%)
QGEN gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 58 industry peers in the Life Sciences Tools & Services industry. Both the health and profitability get an excellent rating, making QGEN a very profitable company, without any liquidiy or solvency issues. QGEN is not valued too expensively and it also shows a decent growth rate. These ratings would make QGEN suitable for quality investing!
1. Profitability
1.1 Basic Checks
QGEN had positive earnings in the past year.
QGEN had a positive operating cash flow in the past year.
Each year in the past 5 years QGEN has been profitable.
Each year in the past 5 years QGEN had a positive operating cash flow.
1.2 Ratios
The Return On Assets of QGEN (6.19%) is better than 82.76% of its industry peers.
QGEN's Return On Equity of 11.11% is amongst the best of the industry. QGEN outperforms 82.76% of its industry peers.
The Return On Invested Capital of QGEN (7.44%) is better than 79.31% of its industry peers.
The Average Return On Invested Capital over the past 3 years for QGEN is significantly below the industry average of 13.53%.
The last Return On Invested Capital (7.44%) for QGEN is above the 3 year average (7.25%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.19% | ||
| ROE | 11.11% | ||
| ROIC | 7.44% |
ROA(3y)4.59%
ROA(5y)5.65%
ROE(3y)7.84%
ROE(5y)10.58%
ROIC(3y)7.25%
ROIC(5y)7.96%
1.3 Margins
With an excellent Profit Margin value of 19.58%, QGEN belongs to the best of the industry, outperforming 94.83% of the companies in the same industry.
QGEN's Profit Margin has declined in the last couple of years.
The Operating Margin of QGEN (27.02%) is better than 96.55% of its industry peers.
In the last couple of years the Operating Margin of QGEN has grown nicely.
QGEN has a better Gross Margin (64.10%) than 86.21% of its industry peers.
QGEN's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 27.02% | ||
| PM (TTM) | 19.58% | ||
| GM | 64.1% |
OM growth 3Y-5.04%
OM growth 5Y4.09%
PM growth 3Y-42.96%
PM growth 5YN/A
GM growth 3Y-0.32%
GM growth 5Y-0.63%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so QGEN is destroying value.
QGEN has less shares outstanding than it did 1 year ago.
Compared to 5 years ago, QGEN has less shares outstanding
The debt/assets ratio for QGEN has been reduced compared to a year ago.
2.2 Solvency
QGEN has an Altman-Z score of 3.62. This indicates that QGEN is financially healthy and has little risk of bankruptcy at the moment.
QGEN has a better Altman-Z score (3.62) than 68.97% of its industry peers.
QGEN has a debt to FCF ratio of 4.50. This is a neutral value as QGEN would need 4.50 years to pay back of all of its debts.
The Debt to FCF ratio of QGEN (4.50) is better than 72.41% of its industry peers.
A Debt/Equity ratio of 0.45 indicates that QGEN is not too dependend on debt financing.
The Debt to Equity ratio of QGEN (0.45) is worse than 60.34% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.45 | ||
| Debt/FCF | 4.5 | ||
| Altman-Z | 3.62 |
ROIC/WACC0.95
WACC7.85%
2.3 Liquidity
A Current Ratio of 2.60 indicates that QGEN has no problem at all paying its short term obligations.
QGEN has a Current ratio of 2.60. This is comparable to the rest of the industry: QGEN outperforms 48.28% of its industry peers.
QGEN has a Quick Ratio of 2.30. This indicates that QGEN is financially healthy and has no problem in meeting its short term obligations.
With a Quick ratio value of 2.30, QGEN perfoms like the industry average, outperforming 51.72% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.6 | ||
| Quick Ratio | 2.3 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an nice 9.62% over the past year.
The Earnings Per Share has been growing by 8.40% on average over the past years. This is quite good.
Looking at the last year, QGEN shows a small growth in Revenue. The Revenue has grown by 5.32% in the last year.
The Revenue has been growing slightly by 5.32% on average over the past years.
EPS 1Y (TTM)9.62%
EPS 3Y-6.66%
EPS 5Y8.4%
EPS Q2Q%4.04%
Revenue 1Y (TTM)5.32%
Revenue growth 3Y-4.22%
Revenue growth 5Y5.32%
Sales Q2Q%6.09%
3.2 Future
The Earnings Per Share is expected to grow by 8.80% on average over the next years. This is quite good.
QGEN is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 7.89% yearly.
EPS Next Y8.55%
EPS Next 2Y8.08%
EPS Next 3Y8.5%
EPS Next 5Y8.8%
Revenue Next Year5.25%
Revenue Next 2Y5.45%
Revenue Next 3Y5.86%
Revenue Next 5Y7.89%
3.3 Evolution
The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 20.30 indicates a rather expensive valuation of QGEN.
Based on the Price/Earnings ratio, QGEN is valued cheaper than 87.93% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 26.15. QGEN is valued slightly cheaper when compared to this.
A Price/Forward Earnings ratio of 18.53 indicates a rather expensive valuation of QGEN.
89.66% of the companies in the same industry are more expensive than QGEN, based on the Price/Forward Earnings ratio.
When comparing the Price/Forward Earnings ratio of QGEN to the average of the S&P500 Index (36.12), we can say QGEN is valued slightly cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 20.3 | ||
| Fwd PE | 18.53 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, QGEN is valued cheaply inside the industry as 91.38% of the companies are valued more expensively.
Based on the Price/Free Cash Flow ratio, QGEN is valued cheaper than 86.21% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 22.07 | ||
| EV/EBITDA | 14.19 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates QGEN does not grow enough to justify the current Price/Earnings ratio.
The excellent profitability rating of QGEN may justify a higher PE ratio.
PEG (NY)2.37
PEG (5Y)2.42
EPS Next 2Y8.08%
EPS Next 3Y8.5%
5. Dividend
5.1 Amount
With a yearly dividend of 0.55%, QGEN is not a good candidate for dividend investing.
QGEN's Dividend Yield is rather good when compared to the industry average which is at 0.49. QGEN pays more dividend than 94.83% of the companies in the same industry.
Compared to an average S&P500 Dividend Yield of 2.41, QGEN's dividend is way lower than the S&P500 average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.55% |
5.2 History
QGEN does not have a reliable dividend history as it only pays dividend since a couple or years.
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
DPN/A
EPS Next 2Y8.08%
EPS Next 3Y8.5%
48.1
-0.46 (-0.95%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners89.95%
Inst Owner Change-18.51%
Ins Owners0.44%
Ins Owner ChangeN/A
Market Cap10.43B
Revenue(TTM)2.07B
Net Income(TTM)405.37M
Analysts74.17
Price Target51.67 (7.42%)
Short Float %2.86%
Short Ratio5.25
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.55% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-Date
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-0.14%
Min EPS beat(2)-2.4%
Max EPS beat(2)2.11%
EPS beat(4)2
Avg EPS beat(4)0.92%
Min EPS beat(4)-3.85%
Max EPS beat(4)7.8%
EPS beat(8)5
Avg EPS beat(8)1.59%
EPS beat(12)8
Avg EPS beat(12)2.59%
EPS beat(16)12
Avg EPS beat(16)5.18%
Revenue beat(2)0
Avg Revenue beat(2)-0.42%
Min Revenue beat(2)-0.72%
Max Revenue beat(2)-0.12%
Revenue beat(4)1
Avg Revenue beat(4)-0.33%
Min Revenue beat(4)-1.92%
Max Revenue beat(4)1.43%
Revenue beat(8)1
Avg Revenue beat(8)-0.6%
Revenue beat(12)2
Avg Revenue beat(12)-0.64%
Revenue beat(16)6
Avg Revenue beat(16)0.46%
PT rev (1m)-1.37%
PT rev (3m)-1.98%
EPS NQ rev (1m)-1.93%
EPS NQ rev (3m)-1.69%
EPS NY rev (1m)0%
EPS NY rev (3m)0.63%
Revenue NQ rev (1m)-1.91%
Revenue NQ rev (3m)-1.91%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.14%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 20.3 | ||
| Fwd PE | 18.53 | ||
| P/S | 5.04 | ||
| P/FCF | 22.07 | ||
| P/OCF | 15.86 | ||
| P/B | 2.86 | ||
| P/tB | 13.07 | ||
| EV/EBITDA | 14.19 |
EPS(TTM)2.37
EY4.93%
EPS(NY)2.6
Fwd EY5.4%
FCF(TTM)2.18
FCFY4.53%
OCF(TTM)3.03
OCFY6.31%
SpS9.55
BVpS16.83
TBVpS3.68
PEG (NY)2.37
PEG (5Y)2.42
Graham Number29.96
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.19% | ||
| ROE | 11.11% | ||
| ROCE | 10.03% | ||
| ROIC | 7.44% | ||
| ROICexc | 10.67% | ||
| ROICexgc | 39.98% | ||
| OM | 27.02% | ||
| PM (TTM) | 19.58% | ||
| GM | 64.1% | ||
| FCFM | 22.82% |
ROA(3y)4.59%
ROA(5y)5.65%
ROE(3y)7.84%
ROE(5y)10.58%
ROIC(3y)7.25%
ROIC(5y)7.96%
ROICexc(3y)9.42%
ROICexc(5y)10.13%
ROICexgc(3y)34.6%
ROICexgc(5y)42.77%
ROCE(3y)9.77%
ROCE(5y)10.73%
ROICexgc growth 3Y-31.24%
ROICexgc growth 5Y-2.41%
ROICexc growth 3Y-13.09%
ROICexc growth 5Y6.48%
OM growth 3Y-5.04%
OM growth 5Y4.09%
PM growth 3Y-42.96%
PM growth 5YN/A
GM growth 3Y-0.32%
GM growth 5Y-0.63%
F-Score8
Asset Turnover0.32
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.45 | ||
| Debt/FCF | 4.5 | ||
| Debt/EBITDA | 2.17 | ||
| Cap/Depr | 97.52% | ||
| Cap/Sales | 8.94% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 87.76% | ||
| Profit Quality | 116.56% | ||
| Current Ratio | 2.6 | ||
| Quick Ratio | 2.3 | ||
| Altman-Z | 3.62 |
F-Score8
WACC7.85%
ROIC/WACC0.95
Cap/Depr(3y)78.4%
Cap/Depr(5y)95.94%
Cap/Sales(3y)7.97%
Cap/Sales(5y)9.87%
Profit Quality(3y)273.85%
Profit Quality(5y)189.74%
High Growth Momentum
Growth
EPS 1Y (TTM)9.62%
EPS 3Y-6.66%
EPS 5Y8.4%
EPS Q2Q%4.04%
EPS Next Y8.55%
EPS Next 2Y8.08%
EPS Next 3Y8.5%
EPS Next 5Y8.8%
Revenue 1Y (TTM)5.32%
Revenue growth 3Y-4.22%
Revenue growth 5Y5.32%
Sales Q2Q%6.09%
Revenue Next Year5.25%
Revenue Next 2Y5.45%
Revenue Next 3Y5.86%
Revenue Next 5Y7.89%
EBIT growth 1Y18.55%
EBIT growth 3Y-9.05%
EBIT growth 5Y9.63%
EBIT Next Year57.27%
EBIT Next 3Y22.23%
EBIT Next 5Y15.78%
FCF growth 1Y71.67%
FCF growth 3Y5.12%
FCF growth 5Y55.1%
OCF growth 1Y52.1%
OCF growth 3Y1.77%
OCF growth 5Y15.28%
QIAGEN N.V. / QGEN FAQ
Can you provide the ChartMill fundamental rating for QIAGEN N.V.?
ChartMill assigns a fundamental rating of 6 / 10 to QGEN.
What is the valuation status of QIAGEN N.V. (QGEN) stock?
ChartMill assigns a valuation rating of 6 / 10 to QIAGEN N.V. (QGEN). This can be considered as Fairly Valued.
What is the profitability of QGEN stock?
QIAGEN N.V. (QGEN) has a profitability rating of 8 / 10.
What are the PE and PB ratios of QIAGEN N.V. (QGEN) stock?
The Price/Earnings (PE) ratio for QIAGEN N.V. (QGEN) is 20.3 and the Price/Book (PB) ratio is 2.86.